ENVÍO GRATIS - PAGO SEGURO - GARANTÍA DE DEVOLUCIÓN DE DINERO Necesitas ayuda?

Carrito de compras


IRESSA-A boon to colon cancer

In-silico studies on Iressa drug inhibiting Epidermal growth factor receptor(EGFR) involved in colon cancer
por Saprativ Das - Vendido por Dodax EU
Condición: Nuevo
47,61 €
IVA incluído - Envío GRATIS
Saprativ Das IRESSA-A boon to colon cancer
Saprativ Das - IRESSA-A boon to colon cancer

¿Le gusta este producto? ¡Compártalo con todo el mundo!

47,61 € incl. IVA
Solo 1 artículos disponibles Solo 2 artículos disponibles
Entrega: entre 2021-03-09 y 2021-03-11
Ventas y envío: Dodax EU

Descripción

The epidermal growth factor receptor (EGFR) is under investigation as a therapeutic target for cancers. Colon cancer cell lines are variably dependent on autocrine stimulation of EGFR. This book therefore,examines the effects of a selective EGFR tyrosine kinase inhibitor, Gefitinib ( Iressa', ZD1839), on proliferation and survival of colon cancer cell lines whose autonomous proliferation is either EGFR ligand dependent or EGFR ligand independent. Using computational approach , different structural analogues were developed for Iressa, how it inhibits the epidermal growth factor kinase ; the studies include nature of the colon cancer and how Iressa work to stop cancer and also explains the ligand binding in EGFR kinase. The consequences help to understand the nature of epidermal growth factor receptor kinase and how to inhibit intra and extra cellular signal. The In-silico properties facilitate more efficient design of screening libraries and serves as a foundation for numerous ADME compound profiling and drug ability assessments along the drug discovery value chain. It also helps to stop the cancer development; a new guideline for the design of inhibitors.

Contribuyente

Autor Saprativ Das

Información

DUIN 1GJ9COFQBGV

GTIN 9783844311174

Idioma Inglés

Número de páginas 76

Product type Libro de bolsillo

47,61 €
Utilizamos cookies en nuestro sitio web para que nuestros servicios sean más eficientes y más fáciles de usar. Por lo tanto, seleccione "Aceptar cookies". Lea nuestra Política de privacidad para obtener más información.